

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 9.0 Revision Date: 2024/04/06 SDS Number: 49939-00023 Date of last issue: 2023/09/30
Date of first issue: 2015/01/26

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Losartan / Amlodipine Besylate Formulation

Supplier's company name, address and phone number

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

E-mail address : EHSSTEWARD@organon.com

Emergency telephone number : +1-215-631-6999

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Serious eye damage/eye irritation : Category 1

Skin sensitisation : Category 1

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H317 May cause an allergic skin reaction.
H318 Causes serious eye damage.
H360D May damage the unborn child.
H362 May cause harm to breast-fed children.

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read and understood.
 P260 Do not breathe dust.
 P263 Avoid contact during pregnancy and while nursing.
 P264 Wash skin thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.
 P272 Contaminated work clothing should not be allowed out of the workplace.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.
 P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.
 P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
 P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and out- : Contact with dust can cause mechanical irritation or drying of
 lines of the emergency as- the skin.
 sumed May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	>= 60 - < 70	
Losartan	124750-99-8	>= 10 - < 20	

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 9.0 Revision Date: 2024/04/06 SDS Number: 49939-00023 Date of last issue: 2023/09/30
Date of first issue: 2015/01/26

Amlodipine Besylate	652969-01-2	$\geq 1 - < 2.5$	
Titanium dioxide	13463-67-7	$> 0 - < 10$	1-558, 5-5225
2,6-Di-tert-butyl-p-cresol	128-37-0	$\geq 0.0025 - < 0.025$	3-540, 9-1805

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.
Causes serious eye damage.
May damage the unborn child.
May cause harm to breast-fed children.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Hazardous combustion products	:	Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE**Handling**

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

- Advice on safe handling : Avoid contact during pregnancy and while nursing.
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.

Storage

- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Reference concentration / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Losartan	124750-99-8	TWA	100 µg/m ³ (OEB 2)	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal
Titanium dioxide	13463-67-7	OEL-M (Respirable)	1.5 mg/m ³ (Titanium)	JP OEL JSOH

Losartan / Amlodipine Besylate Formulation

Version 9.0 Revision Date: 2024/04/06 SDS Number: 49939-00023 Date of last issue: 2023/09/30
 Date of first issue: 2015/01/26

		particulate matter)		
	Further information: Group 2B:		possibly carcinogenic to humans	
		OEL-M (Total particulate matter)	2 mg/m ³ (Titanium)	JP OEL JSOH
	Further information: Group 2B:		possibly carcinogenic to humans	
2,6-Di-tert-butyl-p-cresol	128-37-0	TWA (Inhalable fraction and vapor)	2 mg/m ³	ACGIH

Engineering measures : Minimize workplace exposure concentrations.
 Apply measures to prevent dust explosions.
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type
 Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
 Chemical resistant goggles must be worn.
 If splashes are likely to occur, wear:
 Face-shield

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
 Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : No data available

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 9.0 Revision Date: 2024/04/06 SDS Number: 49939-00023 Date of last issue: 2023/09/30
Date of first issue: 2015/01/26

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit
Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Decomposition temperature : No data available

pH : No data available

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Density and / or relative density
Relative density : No data available

Density : No data available

Relative vapour density : No data available

Explosive properties : Not explosive

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	No data available
Particle size	:	

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Expert judgement

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Losartan:

Acute oral toxicity	:	LD50 (Mouse): 1,257 - 1,590 mg/kg
---------------------	---	-----------------------------------

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

LDLo (Rat): 200 mg/kg

LDLo (Mouse): 400 mg/kg

Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
 Exposure time: 4 h
 Test atmosphere: dust/mist
 Assessment: The substance or mixture has no acute inhalation toxicity

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
 Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
 Method: OECD Test Guideline 402
 Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Losartan:**

Species : Rabbit
 Result : Mild skin irritation

Titanium dioxide:

Species : Rabbit
 Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
 Method : OECD Test Guideline 404
 Result : No skin irritation
 Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Causes serious eye damage.

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Components:**Losartan:**

Species	: Rabbit
Result	: Severe irritation

Amlodipine Besylate:

Species	: Rabbit
Result	: Severe irritation

Titanium dioxide:

Species	: Rabbit
Result	: No eye irritation

2,6-Di-tert-butyl-p-cresol:

Species	: Rabbit
Result	: No eye irritation
Method	: OECD Test Guideline 405
Remarks	: Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:**Losartan:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Assessment	: Probability or evidence of skin sensitisation in humans
Result	: positive

Titanium dioxide:

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Result	: negative

2,6-Di-tert-butyl-p-cresol:

Test Type	: Human repeat insult patch test (HRIPT)
Exposure routes	: Skin contact
Species	: Humans
Result	: negative

Losartan / Amlodipine Besylate Formulation

Version
9.0Revision Date:
2024/04/06SDS Number:
49939-00023Date of last issue: 2023/09/30
Date of first issue: 2015/01/26**Germ cell mutagenicity**

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Losartan:

Genotoxicity in vitro	:	Test Type: in vitro assay Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster ovary cells Result: negative
		Test Type: Alkaline elution assay Result: negative
		Test Type: Chromosomal aberration Result: negative
Genotoxicity in vivo	:	Test Type: Chromosomal aberration Result: negative

Amlodipine Besylate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: negative

Titanium dioxide:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test Species: Mouse Result: negative

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
	:	Result: negative
	:	Test Type: In vitro mammalian cell gene mutation test
	:	Result: negative
	:	Test Type: Chromosome aberration test in vitro
	:	Result: negative
Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	:	Species: Rat
	:	Application Route: Ingestion
	:	Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Losartan:

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	92 weeks
Dose	:	200 mg/kg body weight
Result	:	negative

Species	:	Rat
Application Route	:	Oral
Exposure time	:	105 weeks
Dose	:	270 mg/kg body weight
Result	:	negative

Amlodipine Besylate:

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Titanium dioxide:

Species	: Rat
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: positive
Remarks	: The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment	: Limited evidence of carcinogenicity in inhalation studies with animals.
------------------------------	---

2,6-Di-tert-butyl-p-cresol:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 22 Months
Result	: negative

Reproductive toxicity

May damage the unborn child.
May cause harm to breast-fed children.

Components:**Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

Losartan:

Effects on fertility	: Test Type: Fertility Species: Rat, female Application Route: Oral Fertility: LOAEL: 200 mg/kg body weight Result: female reproductive effects Remarks: Maternal toxicity observed.
Effects on foetal development	: Test Type: Development Species: Rabbit Application Route: Oral General Toxicity Maternal: NOAEL: 10 mg/kg body weight Developmental Toxicity: NOAEL F1: 20 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

Losartan / Amlodipine Besylate Formulation

Version 9.0	Revision Date: 2024/04/06	SDS Number: 49939-00023	Date of last issue: 2023/09/30 Date of first issue: 2015/01/26
----------------	------------------------------	----------------------------	---

spring were detected only at high maternally toxic doses, No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: Fetotoxicity, No teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Studies indicating a hazard to babies during the lactation period

Amlodipine Besylate:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Fertility: NOAEL: 10 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
Fertility: NOAEL: 25 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: Effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Ingestion
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Effects on foetal development
Remarks: Maternal toxicity observed.

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

	Effects on foetal development	:	Result: negative Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative
--	-------------------------------	---	--

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Components:**Losartan:**

Exposure routes	:	Ingestion
Target Organs	:	Blood, Cardio-vascular system, Stomach, Kidney
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment	:	No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.
------------	---	--

Repeated dose toxicity**Components:****Cellulose:**

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Losartan:

Species	:	Rat
LOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	309 d
Number of exposures	:	daily
Target Organs	:	Blood, Kidney, Cardio-vascular system, Stomach

Species	:	Dog
NOAEL	:	5 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Symptoms	:	Salivation, Vomiting

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Species	: Dog
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 53 Weeks
Number of exposures	: daily
Symptoms	: Salivation, Vomiting

Amlodipine Besylate:

Species	: Rat
NOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Remarks	: No significant adverse effects were reported

Titanium dioxide:

Species	: Rat
NOAEL	: 24,000 mg/kg
Application Route	: Ingestion
Exposure time	: 28 Days

Species	: Rat
NOAEL	: 10 mg/m ³
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 2 yr

2,6-Di-tert-butyl-p-cresol:

Species	: Rat
NOAEL	: 25 mg/kg
Application Route	: Ingestion
Exposure time	: 22 Months

Aspiration toxicity

Not classified based on available information.

Components:**Losartan:**

|| No aspiration toxicity classification

Experience with human exposure**Components:****Losartan:**

Eye contact	: Symptoms: Eye irritation
Ingestion	: Symptoms: hypotension, tachycardia

Amlodipine Besylate:

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Eye contact	: Symptoms: Severe irritation
Ingestion	: Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Oedema, Palpitation

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

Losartan:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 929 mg/l Exposure time: 96 h Method: FDA 4.11
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 331 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: NOEC (Microcystis aeruginosa (blue-green algae)): 949 mg/l Exposure time: 10 d Method: FDA 4.01 NOEC (Selenastrum capricornutum (green algae)): 143 mg/l Exposure time: 10 d Method: FDA 4.01
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 10 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 100 mg/l Exposure time: 21 d Method: OECD Test Guideline 211

Amlodipine Besylate:

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 3.2 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l Exposure time: 72 h

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Method: OECD Test Guideline 201

Titanium dioxide:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l Exposure time: 72 h
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 0.57 mg/l Exposure time: 96 h Method: Directive 67/548/EEC, Annex V, C.1.
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.48 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	1
Toxicity to fish (Chronic toxicity)	:	NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l Exposure time: 30 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.316 mg/l Exposure time: 21 d
M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: > 10,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Persistence and degradability**Components:****Cellulose:**

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

Losartan:

Stability in water	:	Hydrolysis: < 10 %(5 d)
--------------------	---	-------------------------

2,6-Di-tert-butyl-p-cresol:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 4.5 % Exposure time: 28 d Method: OECD Test Guideline 301C
------------------	---	--

Bioaccumulative potential**Components:****Losartan:**

Partition coefficient: n-octanol/water	:	log Pow: 1.2
--	---	--------------

Amlodipine Besylate:

Partition coefficient: n-octanol/water	:	log Pow: 3
--	---	------------

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation	:	Species: Cyprinus carpio (Carp) Bioconcentration factor (BCF): 330 - 1,800
-----------------	---	---

Partition coefficient: n-octanol/water	:	log Pow: 5.1
--	---	--------------

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal.

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 9.0 Revision Date: 2024/04/06 SDS Number: 49939-00023 Date of last issue: 2023/09/30
Date of first issue: 2015/01/26

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Losartan / Amlodipine Besylate Formulation

Version 9.0 Revision Date: 2024/04/06 SDS Number: 49939-00023 Date of last issue: 2023/09/30
Date of first issue: 2015/01/26

Chemical Substance Control Law

Priority Assessment Chemical Substance

Chemical name	Number
2,6-Di-tert-butyl-4-methylphenol	64

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
Titanium(IV) oxide	>0 - <10	-

Substances Subject to be Indicated Names

Not applicable

Substances Subject to be Indicated Names

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
9.0	2024/04/06	49939-00023	Date of first issue: 2015/01/26

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
JP OEL JSOH	:	Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
JP OEL JSOH / OEL-M	:	Occupational Exposure Limit-Mean

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.